|
1
|
Broaddus VC: Asbestos, the mesothelial
cell and malignancy: a matter of life or death. Am J Respir Cell
Mol Biol. 17:657–659. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Morinaga K, Kishimoto T, Sakatani M, Akira
M, Yokoyama K and Sera Y: Asbestos-related lung cancer and
mesothelioma in Japan. Ind Health. 39:65–74. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dufresne A, Bégin R, Churg A and Massé S:
Mineral fiber content of lungs in patients with mesothelioma
seeking compensation in Quebec. Am J Respir Crit Care Med.
153:711–718. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Light RW: Primary tumors of the pleura:
malignant mesotheliomas, solitary fibrous tumors, body cavity
lymphoma, and pyothorax-associated lymphoma. Pleural Diseases. 4th
edn. Lippincott Williams and Wilkins; Philadelphia, PA: pp.
135–150. 2001
|
|
5
|
Britton M: The epidemiology of
mesothelioma. Semin Oncol. 29:18–25. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zellos L and Sugarbaker DJ: Current
surgical management of malignant pleural mesothelioma. Curr Oncol
Rep. 4:354–360. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vogelzang NJ, Rusthoven JJ, Symanowski J,
Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S,
Manegold C, Niyikiza C and Paoletti P: Phase III study of
pemetrexed in combination with cisplatin versus cisplatin alone in
patients with malignant pleural mesothelioma. J Clin Oncol.
21:2636–2644. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Manning BD and Cantley LC: AKT/PKB
signaling: navigating downstream. Cell. 129:1261–1274. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Marte BM and Downward J: PKB/Akt:
connecting phosphoinositide 3-kinase to cell survival and beyond.
Trends Biochem Sci. 22:355–358. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Roberts PJ and Der CJ: Targeting the
Raf-MEK-ERK mitogen activated protein kinase cascade for the
treatment of cancer. Oncogene. 26:3291–3310. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sebolt-Leopold JS, Dudley DT, Herrera R,
Van Becelaere K, Wiland A, Gowan RC, Tecle H, Barrett SD, Bridges
A, Przybranowski S, Leopold WR and Saltiel AR: Blockade of the MAP
kinase pathway suppresses growth of colon tumors in vivo. Nat Med.
5:810–816. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hoshino R, Chatani Y, Yamori T, Tsuruo T,
Oka H, Yoshida O, Shimada Y, Ari-i S, Wada H, Fujimoto J and Kohno
M: Constitutive activation of the 41-/43-kDa mitogen-activated
protein kinase signaling pathway in human tumors. Oncogene.
18:813–822. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
de Melo M, Gerbase MW, Curran J and Pache
JC: Phosphorylated extracellular signal-regulated kinases are
significantly increased in malignant mesothelioma. J Histochem
Cytochem. 54:855–861. 2006.PubMed/NCBI
|
|
14
|
Altomare DA, You H, Xiao GH, Ramos-Nino
ME, Skele KL, De Rienzo A, Jhanwar SC, Mossman BT, Kane AB and
Testa JR: Human and mouse mesotheliomas exhibit elevated AKT/PKB
activity, which can be targeted pharmacologically to inhibit tumor
cell growth. Oncogene. 24:6080–6089. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cole GW, Alleva AM, Zuo JT, Sehgal SS,
Yeow WS, Schrump DS and Nguyen DM: Suppression of pro-metastasis
phenotypes expression in malignant pleural mesothelioma by the PI3K
inhibitor LY294002 or the MEK inhibitor U0126. Anticancer Res.
26:809–822. 2006.PubMed/NCBI
|
|
16
|
Yokoyama A, Kohno N, Fujino S, Hamada H,
Inoue Y, Fujioka S and Hiwada K: Origin of heterogeneity of
interleukin-6 (IL-6) levels in malignant pleural effusions. Oncol
Rep. 1:507–511. 1994.PubMed/NCBI
|
|
17
|
Nakataki E, Yano S, Matsumori Y, Goto H,
Kakiuchi S, Muguruma H, Bando Y, Uehara H, Hamada H, Kito K,
Yokoyama A and Sone S: Novel orthotopic implantation of human
malignant pleural mesothelioma (EHMES-10 cells) highly expressing
vascular endothelial growth factor and its receptor. Cancer Sci.
97:183–191. 2006. View Article : Google Scholar
|
|
18
|
Rak-Mardyla A and Gregoraszczuk EL: ERK
1/2 and PI-3 kinase pathways as a potential mechanism of ghrelin
action on cell proliferation and apoptosis in the porcine ovarian
follicular cells. J Physiol Pharmacol. 61:451–458. 2010.PubMed/NCBI
|
|
19
|
Ciofani G, Ricotti L, Danti S, Moscato S,
Nesti C, D’Alessandro D, Dinucci D, Chiellini F, Pietrabissa A,
Petrini M and Menciassi A: Investigation of interactions between
poly-L-lysine-coated boron nitride nanotubes and C2C12 cells:
up-take, cytocompatibility, and differentiation. Int J
Nanomedicine. 5:285–298. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hamaguchi N, Hamada H, Miyoshi S, Irifune
K, Ito R, Miyazaki T and Higaki J: In vitro and in vivo therapeutic
efficacy of the PPAR-γ agonist troglitazone in combination with
cisplatin against malignant pleural mesothelioma cell growth.
Cancer Sci. 101:1955–1964. 2010.
|
|
21
|
Soga Y, Komori H, Miyazaki T, Arita N,
Terada M, Kamada K, Tanaka Y, Fujino T, Hiasa Y, Matsuura B, Onji M
and Nose M: Toll-like receptor 3 signaling induces chronic
pancreatitis through the Fas/Fas ligand-mediated cytotoxicity.
Tohoku J Exp Med. 217:175–184. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wee S, Jagani Z, Xiang KX, Loo A, Dorsch
M, Yao YM, Sellers WR, Lengauer C and Stegmeier F: PI3K pathway
activation mediates resistance to MEK inhibitors in KRAS mutant
cancers. Cancer Res. 69:4286–4293. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bedogni B, Welford SM, Kwan AC,
Ranger-Moore J, Saboda K and Powell MB: Inhibition of
phosphatidylinositol-3-kinase and mitogen-activated protein kinase
kinase 1/2 prevents melanoma development and promotes melanoma
regression in the transgenic TPRas mouse model. Mol Cancer Ther.
5:3071–3077. 2006. View Article : Google Scholar
|
|
24
|
Furuya F, Lu C, Willingham MC and Cheng
SY: Inhibition of phosphatidylinositol 3-kinase delays tumor
progression and blocks metastatic spread in a mouse model of
thyroid cancer. Carcinogenesis. 28:2451–2458. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
McCubrey JA, Steelman LS, Abrams SL, Lee
JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA,
D’Assoro AB, Salisbury JL, Mazzarino MC, Stivala F and Libra M:
Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant
transformation and drug resistance. Adv Enzyme Regul. 46:249–279.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mukohara T, Civiello G, Johnson BE and
Janne PA: Therapeutic targeting of multiple signaling pathways in
malignant pleural mesothelioma. Oncology. 68:500–510. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Robinson BW and Lake RA: Advances in
malignant mesothelioma. N Engl J Med. 353:1591–603. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li Q, Yano S, Ogino H, Wang W, Uehara H,
Nishioka Y and Sone S: The therapeutic efficacy of anti vascular
endothelial growth factor antibody, bevacizumab, and pemetrexed
against orthotopically implanted human pleural mesothelioma cells
in severe combined immunodeficient mice. Clin Cancer Res.
13:5918–5925. 2007. View Article : Google Scholar
|
|
29
|
Yano S, Shinohara H, Herbst RS, Kuniyasu
H, Bucana CD, Ellis LM and Fidler IJ: Production of experimental
malignant pleural effusions is dependent on invasion of the pleura
and expression of vascular endothelial growth factor/vascular
permeability factor by human lung cancer cells. Am J Pathol.
157:1893–1903. 2000. View Article : Google Scholar
|
|
30
|
Rexer BN, Ghosh R and Arteaga CL:
Inhibition of PI3K and MEK: It is all about combinations and
biomarkers. Clin Cancer Res. 15:4518–4520. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rinehart J, Adjei AA, Lorusso PM,
Waterhouse D, Hecht JR, Natale RB, Hamid O, Varterasian M, Asbury
P, Kaldjian EP, Gulyas S, Mitchell DY, Herrera R, Sebolt-Leopold JS
and Meyer MB: Multicenter phase II study of the oral MEK inhibitor,
CI-1040, in patients with advanced non-small-cell lung, breast,
colon, and pancreatic cancer. J Clin Oncol. 22:4456–4462. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hu L, Zaloudek C, Mills GB, Gray J and
Jaffe RB: In vivo and in vitro ovarian carcinoma growth inhibition
by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin
Cancer Res. 6:880–886. 2000.PubMed/NCBI
|
|
33
|
Hu L, Hofmann J, Lu Y, Mills GB and Jaffe
RB: Inhibition of phosphatidylinositol 3′-kinase increases efficacy
of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer
Res. 62:1087–1092. 2002.
|
